Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The prevention and treatment of coronary heart disease is a major challenge in the overall management of the patient with type 2 diabetes. Diabetic dyslipidaemia is an important risk factor and is open to therapeutic intervention. However, as yet there are no primary or secondary coronary heart disease prevention trials of lipid-lowering therapy reported in diabetic populations. In this review, on-going clinical trials of lipid-lowering therapy in specific diabetic populations will be described.

Type

Journal article

Journal

Curr Opin Lipidol

Publication Date

12/2000

Volume

11

Pages

621 - 626

Keywords

Anticholesteremic Agents, Arteriosclerosis, Atorvastatin Calcium, Clinical Trials as Topic, Coronary Disease, Diabetes Mellitus, Type 2, Fenofibrate, Heptanoic Acids, Humans, Hyperlipidemias, Hypolipidemic Agents, Pyrroles, Risk Factors